FDA's Dermatologic Drugs Advisory Committee
Agenda for May 6 meeting includes potential safety issues concerning Reed and Carnrick's Rx anti-lice shampoo Kwell (lindane 1%) raised by new epidemiologic data suggesting an association between the shampoo and development of brain tumors in children. There will be closed committee deliberations in the morning with open discussion starting at 1 p.m. On May 7, beginning at 8:30 a.m., the committee will consider new indications for Schering's Elocon (mometasone furoate 0.1%) ointment and cream for use in children; and for pulse dose/maintenance therapy with high-and super-potent topical corticosteroids in treating psoriasis. Elocon is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. The meeting will be held at FDA's Parklawn Building in Conference Rooms D & E.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth